Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria

NCT ID: NCT03752476

Last Updated: 2018-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-01

Study Completion Date

2019-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the impact of rank of Beta lactam antibiotics on emergence of mutlidrug resistant bacteria colonization in intensive care

It's retrospective case controle study. Cases are colonized patient by multidrug resistant bacteria hospitalized in intensive care during the fist hospitalization in intensive care. Temoin are patients with the same characteristics than case but no colonized by multidrug resistant bacteria.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The emergence of multidrug resistant is a wordwide problem. B lactam resistant increase. The antibiotic prescription impact this problem.

B lactam antibiotic is prescribed everyday in intensive care unit. The switch of antibiotic is common. Antibiotic classes inclue a lot of rank with different spectum that impact the occurrence of resistant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Resistant Infection Antibiotic Resistant Infection Beta Lactam Resistant Bacterial Infection Bacterial Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

case

Patients are colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.

number of Beta lactam class prescription for the same infection

Intervention Type PROCEDURE

Each number of Beta lactam prescription without interruption are compared

control

Patients aren't colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.

number of Beta lactam class prescription for the same infection

Intervention Type PROCEDURE

Each number of Beta lactam prescription without interruption are compared

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

number of Beta lactam class prescription for the same infection

Each number of Beta lactam prescription without interruption are compared

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all patient hospitalized more than 48 hours in intensive care unit in Besançon between january 2016 and december 2017

Exclusion Criteria

* patient under guardianship
* patient allergic to Beta lactam
* colonization with mutidrug resistant the first week of hospitalization in intensive care unit
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Estelle Dossot

Internal

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

ESTELLE DOSSOT

Role: CONTACT

+33645578372

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dossot

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.